Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, child: Ependymoma/Ependymal tumors
Trial Type:  Treatment
Results 1-15 of 15 for your search:
Start Over
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ACNS0831, NCI-2011-02029, CDR0000668560, COG-ACNS0831, NCT01096368
Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596
Carboplatin with or without Vincristine Sulfate in Treating Younger Patients with Previously Untreated Low Grade Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and younger
Trial IDs: LCH 14C03, NCI-2015-01146, 2014-15932, LGG-14C03, NCT02455245
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
Proton Beam Radiation Therapy in Treating Younger Patients with Brain Tumors
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 1 to 25
Trial IDs: 10-206, NCI-2011-00201, NCT01288235
Surgery and Second-Course Radiation Therapy in Treating Younger Patients with Recurrent Ependymoma
Phase: Phase II
Type: Treatment
Age: 1 to 21
Trial IDs: RERTEP, NCI-2014-00906, NCT02125786
Sirolimus and Metronomic Chemotherapy in Treating Younger Patients with Recurrent and/or Refractory Solid or Central Nervous System Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: AFLACST1502, NCI-2015-01637, IRB00082488, NCT02574728
Palbociclib Isethionate in Treating Younger Patients with Recurrent, Progressive, or Refractory Central Nervous System Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: PBTC-042, NCI-2014-00640, NCT02255461
Pomalidomide in Treating Younger Patients with Recurrent, Progressive or Refractory Central Nervous System Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 20
Trial IDs: PBTC-043, NCI-2014-02182, CC-4047-PBTC-043, PPBTC-043_R04PAPP01, NCT02415153
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 21
Trial IDs: NLG2105, NCI-2015-01872, NCT02502708
Risk-Adapted Therapy in Treating Young Children with Brain Tumors
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 3 at diagnosis
Trial IDs: SJYC07, NCI-2011-01193, SJCRH-SJYC07, NCT00602667
Informed Consent to Enroll Younger Patients with Newly Diagnosed Cancer in the Childhood Cancer Research Network
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: 18 and under
Trial IDs: ACCRN07, NCI-2009-00331, CDR0000069496, 10-C-0111, NCT01117168
Conditioning Therapy Followed by Stem Cell Transplant in Treating Patients with High Risk or Relapsed Solid, Central Nervous System, or Germ Cell Tumors
Phase: No phase specified
Type: Treatment
Age: 70 and under
Trial IDs: 2011OC057, NCI-2013-02265, 1107M02641, MT2011-09C, NCT01505569
Cyclophosphamide or Thalidomide after Stem Cell Transplant in Treating Younger Patients with Solid Tumors
Phase: No phase specified
Type: Treatment
Age: 5 to 21
Trial IDs: 201209088, NCI-2012-01541, NCT01661400
Fluorine F 18 Fluorodopa PET/MRI in Predicting Response in Younger Patients with Central Nervous System Tumors
Phase: No phase specified
Type: Diagnostic, Treatment
Age: 21 and under
Trial IDs: 201303069, NCI-2013-00822, NCT01999270
Start Over